---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Heterogeneity of treatment effect"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Heterogeneity of treatment effect. Topics: Summary: heterogeneity evidence for inaxaplin, Inaxaplin: response by cohort in AMPLIFIED (modest proteinuria and type 2 diabetes), Inaxaplin: response by baseline proteinuria range in the phase 2a study, Inaxaplin: APOL1 genotype distribution in the AMPLITUDE phase 2 portion, and 9 further topics. 13 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Summary: heterogeneity evidence for inaxaplin

The sources reviewed report no inaxaplin efficacy results stratified by APOL1 genotype. Of the 64 participants dosed in AMPLITUDE as of the 2024 abstract, 53.1% had the G1/G1, 37.5% the G1/G2, and 9.4% the G2/G2 genotype; efficacy results from that portion have not been published. The differences in response reported to date are by comorbidity and proteinuria level. In AMPLIFIED, the mean change in UACR at week 13 was -42.7% (95% CI -58.3% to -21.1%) in cohort 1 (modest proteinuria, most without diagnosed FSGS) and -17.3% (95% CI -36.3% to 7.2%) in cohort 2 (type 2 diabetes); the confidence intervals were generated post hoc, and the interval for cohort 2 includes no change. In the phase 2a study, the mean UPCR change was -47.7% in the 3 participants with nephrotic-range proteinuria and -47.5% in those with subnephrotic-range proteinuria, and 1 participant with 100% adherence had no reduction. In vitro, inaxaplin inhibited thallium flux in cells expressing G0, G1, and G2 APOL1; a 2026 abstract reports that inaxaplin partially reduced the cytotoxicity of full-length APOL1-G1 and did not rescue toxicity from a nuclear APOL1-G1 fragment produced by cathepsin S. For existing therapies, APOL1 genotype did not modify the effect of blood pressure target or ACE inhibitor treatment on CKD progression in AASK, and did not affect proteinuria response to cyclosporine or mycophenolate mofetil plus dexamethasone in the FSGS Clinical Trial; in AASK, strict blood pressure control was associated with 42% lower mortality in the high-risk genotype group only.

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396); [Li et al. (2026b)](https://doi.org/10.1681/ASN.2026jtffd5vb); [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/); [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/); [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5237400/)

<a id="topic-2.2.2.3-2"></a>

### Inaxaplin: response by cohort in AMPLIFIED (modest proteinuria and type 2 diabetes)

> “In cohort 1, treatment with inaxaplin administered on top of optimized standard of care led to a reduction of -42.7% (95% CI -58.3%, -21.1%) in UACR at Week 13 compared to baseline. UPCR decreased by -44.7% from baseline at Week 13.”
> “In this modest proteinuria cohort, most people were not diagnosed with FSGS.”
> “In cohort 2, treatment with inaxaplin administered on top of optimized standard of care led to a reduction in UACR at Week 13 of -17.3% (95% CI -36.3%, 7.2%) compared to baseline. UPCR decreased by -25.4% from baseline at Week 13.”
> “We are also excited with the treatment effect, though smaller in magnitude, in the type 2 diabetes cohort.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.3-3"></a>

### Inaxaplin: response by baseline proteinuria range in the phase 2a study

> “Reduction in proteinuria was seen in both the nephrotic- and subnephrotic-range groups (mean change in the urinary protein-to-creatinine ratio, −47.7% and −47.5%, respectively) (Table 2) and was unrelated to background standard-care medications.”
> “One participant with subnephrotic-range proteinuria did not have a decrease in proteinuria with inaxaplin therapy in our study. The adherence to treatment in this participant was 100%; neither the lead country investigator nor the treating nephrologist could identify any clinical characteristics that might have influenced the lack of treatment response.”
> “Although only three participants with nephrotic-range proteinuria were enrolled in this study, the results in these participants appeared to be consistent with those observed in participants who had less-severe proteinuria.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.3-4"></a>

### Inaxaplin: APOL1 genotype distribution in the AMPLITUDE phase 2 portion

> “Among 64 participants dosed, 34(53.1%), 24(37.5%), and 6(9.4%) have G1/G1, G1/G2, or G2/G2 genotypes.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="topic-2.2.2.3-5"></a>

### Inaxaplin: in vitro activity against G0, G1, and G2 APOL1

> “Specifically, in cellular assays, inaxaplin blocked the channel function of APOL1 in a concentration-dependent manner, as shown by the reduced APOL1-induced thallium ion flux in tetracycline-inducible APOL1 HEK293 cells (Figure 1A).”
> “Panel A shows the percent inhibition of thallium ion flux in cell lines expressed by the apolipoprotein L1 (APOL1) reference sequence (G0) and disease-associated variants APOL1 G1 and APOL1 G2 as a function of inaxaplin concentration.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.3-6"></a>

### Inaxaplin: preclinical APOL1-G1 fragments resistant to channel inhibition

> “Cytotoxicity assays were used to compare the effects of full-length APOL1-G1 and APOL1-G1 fragments, including their responses to the APOL1 channel inhibitor Inaxaplin.”
> “Notably, Inaxaplin partially reduced cytotoxicity induced by full-length APOL1-G1 but failed to rescue toxicity induced by the nuclear APOL1-G1 fragment.”
> “Our findings support a novel inflammatory mechanism in which IFN-γ promotes Cathepsin S–dependent processing of APOL1-G1 into toxic fragments that contribute to podocyte injury through membrane-independent pathways potentially resistant to current APOL1 channel inhibitors.”

Source: [Li et al. (2026b)](https://doi.org/10.1681/ASN.2026jtffd5vb)

<a id="topic-2.2.2.3-7"></a>

### Inaxaplin: populations not yet studied

> “The effects of inaxaplin therapy in this short-term clinical study involving participants with two APOL1 variants and biopsy-proven focal segmental glomerulosclerosis (a severe, rapidly progressive form of proteinuric CKD) remain to be studied in persons with two APOL1 variants and other types of proteinuric CKD, such as hypertensive kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.3-8"></a>

### Genotype refinement: the p.N264K modifier of APOL1 G2

> “The APOL1 p.N264K variant was recently found to genetically and almost completely negate the effect of G2 risk alleles to levels comparable to G0, and this observation has been replicated in subsequent studies, making APOL1 p.N264K the most robust genetic modifier of APOL1 G2 to date.”
> “Increase utilization of p.N264K in inclusion criteria of clinical trials.”
> “Determine the effects of conventional therapies for FSGS and other glomerular diseases in those with APOL1 high-risk genotypes.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.3-9"></a>

### Blood pressure target and ACE inhibitor by APOL1 genotype: AASK

> “In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.”
> “Although baseline proteinuria was a major predictor of disease progression, it did not significantly modify the effect of APOL1 on progression (P = 0.16 for interaction) (Fig. 1B). In addition, there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction) (Fig. 1C), nor was there a significant interaction between APOL1 status and the randomized antihypertensive medication with respect to progression (P = 0.72 for interaction)”
> “The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

<a id="topic-2.2.2.3-10"></a>

### Mortality with strict blood pressure control by APOL1 genotype: AASK

> “However, a significant interaction was detected between APOL1 risk group and blood pressure control strategy. In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).”

Source: [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5237400/)

<a id="topic-2.2.2.3-11"></a>

### Other modifiers of APOL1-associated progression: AASK

> “Sociodemographic factors and common risk factors for CKD progression do not seem to alter APOL1–related CKD progression. Additional investigation is needed to identify nontraditional factors that may affect the association between APOL1 and progressive CKD.”

Source: [Chen et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4670769/)

<a id="topic-2.2.2.3-12"></a>

### Immunosuppression response by APOL1 genotype: FSGS Clinical Trial

> “APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).”
> “The APOL1 risk genotype did not influence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.2.3-13"></a>

### Baseline progression risk by diabetes status in proteinuric AMKD

> “Almost all subgroups, which were defined by diabetes status and baseline eGFR cutoffs, experienced eGFR decline faster than 3 mL/min per year, with faster declines in patients with diabetes. In the pooled cohort with baseline eGFR below 90 mL/min/1.73 m2, the mean annual eGFR slope was –3.0 mL/min/1.73 m2 (95% CI, –3.3 to –2.7) in patients without diabetes and –4.2 mL/min/1.73 m2 (95% CI, –4.5 to –3.9) in patients with type 2 diabetes.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
